Lipid Nanoparticles Based Multi-Scale Systemic Immune Programming for Cancer Therapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Cancer immunotherapy faces challenges like toxicity and physical barriers in tumors.
• Current cell therapies are complex to manufacture.
• Limitations hinder the broad clinical application of cancer immunotherapies.

Purpose of the Study:

• To present multi-scale systemic immune programming using lipid nanoparticles (LNPs) as a transformative approach for cancer treatment.
• To explore how LNPs can direct immune responses across molecular, cellular, tissue, systemic, and organismal levels.
• To propose a dual-track therapeutic paradigm integrating immune activation and physiological restoration for cancer therapy.

Main Methods:

• Designing lipid nanoparticles (LNPs) for targeted delivery and immune response modulation.
• Utilizing intratumoral mRNA delivery to reprogram the tumor microenvironment.
• Engineering in vivo CAR-T cells and vaccine-driven immune memory using LNPs.
• Developing liver-targeted LNPs for metabolic regulation and host resilience enhancement.

Main Results:

• LNP design regulates mRNA stability, translation, and antigen presentation at molecular and cellular levels.
• Intratumoral mRNA delivery overcomes tumor stromal barriers and immunosuppression.
• LNPs coordinate systemic immune responses, including in vivo CAR-T engineering and vaccine-induced memory.
• Liver-targeted LNPs restore metabolic function, reverse cachexia, and improve host resilience.

Conclusions:

• Lipid nanoparticles serve as programmable platforms for multi-scale immune programming in cancer therapy.
• A dual-track approach integrating tumor-directed immunity and host restoration offers a new paradigm for cancer treatment.
• LNP-based therapies can treat cancer as a systemic immune-metabolic disorder, moving beyond a localized disease model.